Silva Pharmaceuticals Limited (DSE: SILVAPHL)
Bangladesh
· Delayed Price · Currency is BDT 13.90
-0.20 (-1.42%)
At close: Sep 12, 2024
Silva Pharmaceuticals Balance Sheet
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2016 |
| Cash & Equivalents | 90.78 | 28.64 | 36.43 | 58.66 | 36.41 | 42.39 | Upgrade
|
| Short-Term Investments | 87.75 | 152.72 | 225.04 | 211.67 | 203.04 | 251.8 | Upgrade
|
| Cash & Short-Term Investments | 178.53 | 181.37 | 261.47 | 270.33 | 239.45 | 294.19 | Upgrade
|
| Cash Growth | -15.16% | -30.64% | -3.28% | 12.90% | -18.61% | 117.44% | Upgrade
|
| Accounts Receivable | 252.85 | 257.35 | 255.05 | 269.91 | 260 | 254.96 | Upgrade
|
| Other Receivables | - | 1.97 | 2.56 | 2.3 | 3.43 | 4.3 | Upgrade
|
| Receivables | 252.85 | 259.32 | 257.61 | 272.21 | 263.43 | 259.26 | Upgrade
|
| Inventory | 489.29 | 493.72 | 482.29 | 464.18 | 444.38 | 397.46 | Upgrade
|
| Other Current Assets | 81.97 | 66.02 | 61.79 | 68.21 | 143.03 | 109.61 | Upgrade
|
| Total Current Assets | 1,003 | 1,000 | 1,063 | 1,075 | 1,090 | 1,061 | Upgrade
|
| Property, Plant & Equipment | 1,464 | 1,501 | 1,480 | 1,371 | 1,365 | 1,241 | Upgrade
|
| Other Intangible Assets | 1.26 | 1.36 | 1.51 | 1.68 | 1.18 | - | Upgrade
|
| Total Assets | 2,467 | 2,503 | 2,545 | 2,447 | 2,456 | 2,302 | Upgrade
|
| Accounts Payable | 7.75 | 6.99 | 6.9 | 6.25 | 6.54 | 4.39 | Upgrade
|
| Accrued Expenses | 24.3 | 12.43 | 16.25 | 15.28 | 14.74 | 14.23 | Upgrade
|
| Short-Term Debt | 42.24 | 55.84 | 91.01 | 29.14 | 26.68 | - | Upgrade
|
| Current Portion of Leases | 1.23 | 1.42 | 2.34 | 5.67 | 5.72 | - | Upgrade
|
| Current Income Taxes Payable | - | 7.9 | 19.03 | 30.63 | 104.82 | 71.13 | Upgrade
|
| Other Current Liabilities | 0.26 | 1.62 | 2.59 | 1.52 | 1.33 | - | Upgrade
|
| Total Current Liabilities | 75.78 | 86.19 | 138.11 | 88.48 | 159.84 | 89.76 | Upgrade
|
| Long-Term Leases | 3.36 | 4.6 | 5.75 | 7.9 | 13.28 | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | 78.44 | 77.86 | 75.68 | 80.3 | 84.98 | 78.52 | Upgrade
|
| Total Liabilities | 157.59 | 168.65 | 219.54 | 176.68 | 258.1 | 168.28 | Upgrade
|
| Common Stock | 1,365 | 1,365 | 1,365 | 1,365 | 1,365 | 1,300 | Upgrade
|
| Retained Earnings | 944.84 | 969.08 | 960.2 | 905.47 | 833.11 | 833.44 | Upgrade
|
| Shareholders' Equity | 2,310 | 2,334 | 2,325 | 2,270 | 2,198 | 2,133 | Upgrade
|
| Total Liabilities & Equity | 2,467 | 2,503 | 2,545 | 2,447 | 2,456 | 2,302 | Upgrade
|
| Total Debt | 46.83 | 61.86 | 99.09 | 42.71 | 45.69 | - | Upgrade
|
| Net Cash (Debt) | 131.7 | 119.51 | 162.38 | 227.62 | 193.76 | 294.19 | Upgrade
|
| Net Cash Growth | -2.84% | -26.40% | -28.67% | 17.48% | -34.14% | 710.51% | Upgrade
|
| Net Cash Per Share | 0.96 | 0.88 | 1.19 | 1.67 | 1.42 | 2.16 | Upgrade
|
| Filing Date Shares Outstanding | 136.5 | 136.5 | 136.5 | 136.5 | 136.5 | 136.5 | Upgrade
|
| Total Common Shares Outstanding | 136.5 | 136.5 | 136.5 | 136.5 | 136.5 | 136.5 | Upgrade
|
| Working Capital | 926.86 | 914.23 | 925.05 | 986.45 | 930.44 | 970.76 | Upgrade
|
| Book Value Per Share | 16.92 | 17.10 | 17.03 | 16.63 | 16.10 | 15.63 | Upgrade
|
| Tangible Book Value | 2,309 | 2,333 | 2,324 | 2,269 | 2,197 | 2,133 | Upgrade
|
| Tangible Book Value Per Share | 16.91 | 17.09 | 17.02 | 16.62 | 16.09 | 15.63 | Upgrade
|
| Land | - | 342.77 | 342.77 | 342.77 | 340.78 | 321.01 | Upgrade
|
| Buildings | - | 424.09 | 424.09 | 424.09 | 424.09 | 420.84 | Upgrade
|
| Machinery | - | 1,090 | 1,072 | 998.72 | 980.87 | 946.56 | Upgrade
|
| Construction In Progress | - | 343.47 | 274.25 | 178.47 | 121.79 | 8.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.